An Open-Label, Single-Dose, Nonrandomized Study Of The Mass Balance And Metabolic Disposition Of Orally Administered 14C-Labeled SAM-531 In Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 28 Jul 2014
At a glance
- Drugs Cerlapirdine (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Wyeth
- 27 Aug 2009 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
- 27 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 31 Jul 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.